Round up of recent biotech milestones and activity
Industry analysts still point to possible forecast the Biotech sector remains a top performer - not only for 2015, but is projected over several years at this point to improve as biopharmaceutical companies forge ahead developing the newest treatments for diseases, cancer drug therapies and array of illnesses, according to FinancialNewsMedia, a third-party provider of publishing and news dissemination services.
For cancer patients alone, more than 22,000 new cases of brain cancer were expected to arise in Americans in 2015, according to the National Cancer Institute, which continues to be a focus for many biotech companies. Biotech companies active with current news and developments include Nascent Biotech (OTC: NBIO), Eleven Biotherapeutics (Nasdaq: EBIO) and Advaxis (Nasdaq: ADXS).
Funding for Nascent’s pritumumab
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze